Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Huperzine A (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Biscayne Neurotherapeutics
- 16 Jan 2018 Status changed from recruiting to completed.
- 19 Oct 2017 Results presented in a Biscayne Neurotherapeutics media release.
- 19 Oct 2017 Results from this trial will be presented at the 8th Annual Sofinnova Japan Biopharma Partnering Conference, according to a Biscayne Neurotherapeutics media release.